146 related articles for article (PubMed ID: 18505128)
21. [Nateglinide].
Notoya Y; Kikuchi M
Nihon Rinsho; 2002 Sep; 60 Suppl 9():371-5. PubMed ID: 12387020
[No Abstract] [Full Text] [Related]
22. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.
Hirschberg Y; Karara AH; Pietri AO; McLeod JF
Diabetes Care; 2000 Mar; 23(3):349-53. PubMed ID: 10868864
[TBL] [Abstract][Full Text] [Related]
23. [symbol: see text] Nateglinide and [symbol: see text] repaglinide for type 2 diabetes?
Drug Ther Bull; 2003 Jul; 41(7):52-4. PubMed ID: 12879789
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of nateglinide in the treatment of type II diabetes mellitus.
Chandrasekharan S; Rao PP; Jayaram S; Jain SD; Ganesan R; Desai A
J Indian Med Assoc; 2002 Jul; 100(7):467-8. PubMed ID: 12674176
[TBL] [Abstract][Full Text] [Related]
25. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus.
Keilson L; Mather S; Walter YH; Subramanian S; McLeod JF
J Clin Endocrinol Metab; 2000 Mar; 85(3):1081-6. PubMed ID: 10720043
[TBL] [Abstract][Full Text] [Related]
26. Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes.
Carroll MF; Gutierrez A; Castro M; Tsewang D; Schade DS
J Clin Endocrinol Metab; 2003 Nov; 88(11):5248-54. PubMed ID: 14602757
[TBL] [Abstract][Full Text] [Related]
27. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.
Rosenstock J; Hassman DR; Madder RD; Brazinsky SA; Farrell J; Khutoryansky N; Hale PM;
Diabetes Care; 2004 Jun; 27(6):1265-70. PubMed ID: 15161773
[TBL] [Abstract][Full Text] [Related]
28. Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes.
Kim MK; Suk JH; Kwon MJ; Chung HS; Yoon CS; Jun HJ; Ko JH; Kim TK; Lee SH; Oh MK; Rhee BD; Park JH
Diabetes Res Clin Pract; 2011 Jun; 92(3):322-8. PubMed ID: 21376417
[TBL] [Abstract][Full Text] [Related]
29. Nateglinide in combination with metformin in Chinese patients with type 2 diabetes mellitus: a post-marketing surveillance study.
Yang JK; Wang L;
Clin Drug Investig; 2013 Mar; 33(3):185-91. PubMed ID: 23338975
[TBL] [Abstract][Full Text] [Related]
30. Nateglinide.
Halas CJ
Am J Health Syst Pharm; 2001 Jul; 58(13):1200-5. PubMed ID: 11449877
[TBL] [Abstract][Full Text] [Related]
31. Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients.
Voytovich MH; Haukereid C; Hjelmesaeth J; Hartmann A; Løvik A; Jenssen T
Clin Transplant; 2007; 21(2):246-51. PubMed ID: 17425753
[TBL] [Abstract][Full Text] [Related]
32. Nateglinide (Starlix): update on a new antidiabetic agent.
Phillips LS; Dunning BE
Int J Clin Pract; 2003; 57(6):535-41. PubMed ID: 12918894
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of mitiglinide versus nateglinide in newly diagnose patients with type 2 diabetes mellitus: a randomized double blind trial.
Li L; Yang M; Li Z; Yan X; Guo H; Pan H; Liu H; Liao Y; Yang G
Diabetes Obes Metab; 2012 Feb; 14(2):187-9. PubMed ID: 21895920
[TBL] [Abstract][Full Text] [Related]
34. Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes.
Gao HW; Xie C; Wang HN; Lin YJ; Hong TP
Acta Pharmacol Sin; 2007 Apr; 28(4):534-9. PubMed ID: 17376293
[TBL] [Abstract][Full Text] [Related]
35. Multicentre, double-blind, randomized study of mitiglinide compared with nateglinide in type 2 diabetes mellitus patients in China.
Gao X;
J Int Med Res; 2009; 37(3):812-21. PubMed ID: 19589264
[TBL] [Abstract][Full Text] [Related]
36. Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure.
Nagai T; Imamura M; Iizuka K; Mori M
Diabetes Res Clin Pract; 2003 Mar; 59(3):191-4. PubMed ID: 12590015
[TBL] [Abstract][Full Text] [Related]
37. Differential therapeutic effects of nateglinide and acarbose on fasting and postprandial lipid profiles: a randomized trial.
Zhou J; Deng Z; Lu J; Li H; Zhang X; Peng Y; Mo Y; Bao Y; Jia W
Diabetes Technol Ther; 2015 Apr; 17(4):229-34. PubMed ID: 25781235
[TBL] [Abstract][Full Text] [Related]
38. Meglitinide analogues for type 2 diabetes mellitus.
Black C; Donnelly P; McIntyre L; Royle PL; Shepherd JP; Thomas S
Cochrane Database Syst Rev; 2007 Apr; 2007(2):CD004654. PubMed ID: 17443551
[TBL] [Abstract][Full Text] [Related]
39. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR
Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362
[TBL] [Abstract][Full Text] [Related]
40. Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis.
Tentolouris N; Boutati E; Karambakalis N; Perrea D; Tselepis AD; Tsoukala C; Kyriaki D; Lourida E; Anastasopoulou I; Karafoullidou A; Raptis SA; Katsilambros N
Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):6-12. PubMed ID: 15871845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]